Related Experiment Video
Updated: Jul 3, 2026

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
Published on: July 21, 2023
Devices in heart failure: potential methods for device-based monitoring of congestive heart failure
Shahzeb M Munir1, Roberta C Bogaev, Ed Sobash
1Atherosclerosis Research Department, Texas Heart Institute at St. Luke's Episcopal Hospital, University of Texas Medical School at Houston, Houston, Texas 77030, USA. shahzeb.sial@gmail.com
Insights
Device-based therapies show promise for managing congestive heart failure (CHF). Early detection of subtle pathophysiologic changes via these devices can aid in preventing worsening conditions and improving patient outcomes.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Congestive heart failure (CHF) is a major cause of hospitalization in the US, accounting for 6.5 million days annually.
- Therapeutic goals include inhibiting CHF progression using pharmacologic and device-based interventions.
- Comorbidities like arrhythmias, ischemia, and valvulopathy significantly impact CHF outcomes.
Purpose of the Study:
- To explore the development of device-based therapies for CHF.
- To investigate methods for improving cardiac reserve and pump function.
- To identify the potential role of devices in early detection of pathophysiologic changes.
Main Methods:
- Review of existing and emerging device-based therapeutic strategies for CHF.
- Analysis of pathophysiologic changes associated with CHF progression and comorbidities.
- Exploration of how device technology can monitor subtle physiological indicators.
Main Results:
- Device-based therapies aim to enhance cardiac function and meet metabolic demands.
- Subtle pathophysiologic changes often precede worsening CHF or onset of comorbidities.
- Timely identification of these changes is crucial for implementing preventive measures.
Conclusions:
- Device-based methods hold significant potential for the early detection of subtle pathophysiologic changes in CHF.
- This early detection may facilitate timely interventions and improve patient management.
- Future research should focus on developing and validating such device-based diagnostic tools.
Abstract:
Congestive heart failure has long been one of the most serious medical conditions in the United States; in fact, in the United States alone, heart failure accounts for 6.5 million days of hospitalization each year. One important goal of heart-failure therapy is to inhibit the progression of congestive heart failure through pharmacologic and device-based therapies. Therefore, there have been efforts to develop device-based therapies aimed at improving cardiac reserve and optimizing pump function to meet metabolic requirements. The course of congestive heart failure is often worsened by other conditions, including new-onset arrhythmias, ischemia and infarction, valvulopathy, decompensation, end-organ damage, and therapeutic refractoriness, that have an impact on outcomes. The onset of such conditions is sometimes heralded by subtle pathophysiologic changes, and the timely identification of these changes may promote the use of preventive measures. Consequently, device-based methods could in the future have an important role in the timely identification of the subtle pathophysiologic changes associated with congestive heart failure.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure VI: Adjunct Therapies
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac muscle...
Heart Failure V: Medical Management
Cardiomyopathy V: Interprofessional Care
Heart Failure IV: Classification and Diagnostic Evaluation

